22.72
+0.89(+4.08%)
Currency In USD
| Previous Close | 21.83 |
| Open | 21.56 |
| Day High | 22.87 |
| Day Low | 21.31 |
| 52-Week High | 45 |
| 52-Week Low | 18.41 |
| Volume | 2.09M |
| Average Volume | 2.64M |
| Market Cap | 2.19B |
| PE | -3.9 |
| EPS | -5.83 |
| Moving Average 50 Days | 27.5 |
| Moving Average 200 Days | 31.34 |
| Change | 0.89 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $356.56 as of February 21, 2026 at a share price of $22.72. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $157.03 as of February 21, 2026 at a share price of $22.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidelines NOVATO, Calif., Feb. 03, 2026 (GLOBE NEWSW
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
GlobeNewswire Inc.
Jan 30, 2026 1:30 PM GMT
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be presented at WORLDSymposium™ 2026 NOVATO, Calif., Jan.